Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Defining the landscape of circRNAs in non-small cell lung cancer and their potential as liquid biopsy biomarkers, a complete review including current methods

  • Pedraz-Valdunciel, Carlos|||0000-0002-3163-2444
  • Rosell, Rafael|||0000-0003-0817-3400
Despite the significant decrease in population-level mortality of lung cancer patients as reflected in the Surveillance Epidemiology and End Results program national database, lung cancer, with non-small cell lung cancer (NSCLC) in the lead, continues to be the most commonly diagnosed cancer and foremost cause of cancer-related death worldwide, primarily due to late-stage diagnosis and ineffective treatment regimens. Although innovative single therapies and their combinations are constantly being tested in clinical trials, the five-year survival rate of late-stage lung cancer remains only 5% (Cancer Research, UK). Henceforth, investigation in the early diagnosis of lung cancer and prediction of treatment response is critical for improving the overall survival of these patients. Circular RNAs (circRNAs) are a re-discovered type of RNAs featuring stable structure and high tissue-specific expression. Evidence has revealed that aberrant circRNA expression plays an important role in carcinogenesis and tumor progression. Further investigation is warranted to assess the value of EV- and platelet-derived circRNAs as liquid biopsy-based readouts for lung cancer detection. This review discusses the origin and biology of circRNAs, and analyzes their present landscape in NSCLC, focusing on liquid biopsies to illustrate the different methodological trends currently available in research. The possible limitations that could be holding back the clinical implementation of circRNAs are also analyzed.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Activation of viral defense signaling in cancer

  • Gonzalez-Cao, Maria
  • Karachaliou, Niki
  • Santarpia, Mariacarmela
  • Viteri, Santiago
  • Meyerhans, Andreas
  • Rosell, Rafael
A coordinated action of innate and adaptive immune responses is required to efficiently combat a microbial infection. It has now become clear that cancer therapies also largely benefit when both arms of the immune response are engaged. In this review, we will briefly describe the current knowledge of innate immunity and how this can be utilized to prime tumors for a better response to immune checkpoint inhibitors. Comments on compounds in development and ongoing clinical trials will be provided., AM is supported by a grant from the Spanish Ministry of Economy, Industry and Compet-itiveness and FEDER grant no. SAF2016-75505-R (AEI/MINEICO/FEDER, UE), and the ‘María de Maeztu’ Programme for Units of Excellence in R&D (MDM-2014-0370). Work in Dr Rosell’s laboratory is partially supported by a grant from La Caixa Foundation, and by a European Grant (ELBA no 765492).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

  • González Cao, María
  • Montagut Viladot, Clara
  • Berrocal Jaime, Alfonso
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the "on-off" schedule. Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516). The trial did not meet its primary endpoint of progression free survival (PFS) improvement. Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule. Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression. NGS analysis demonstrated de novo mutations in resistant cases.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Multiplex analysis of circRNAs from plasma extracellular vesicle-enriched samples for the detection of early-stage non-small cell lung cancer

  • Pedraz-Valdunciel, Carlos
  • Giannoukakos, Stavros
  • Giménez-Capitán, Ana
  • Fortunato, Diogo
  • Filipska, Martyna
  • Bertran-Alamillo, Jordi
  • Bracht, Jillian W.P.
  • Drozdowskyj, Ana
  • Valarezo, Joselyn
  • Zarovni, Natasa
  • Fernández-Hilario, Alberto
  • Hackenberg, Michael
  • Aguilar-Hernández, Andrés
  • Molina-Vila, Miguel Ángel
  • Rosell, Rafael
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients. Methods: EVs were isolated from early-stage LC patients (n = 36) and controls (n = 30). Different volumes of plasma, together with different number of pre-amplification cycles, were tested to reach the best nCounter outcome. Differential expression analysis of circRNAs was performed, along with the testing of different machine learning (ML) methods for the development of a prognostic signature for LC. Results: A combination of 500 μL of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86. Conclusions: This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures., This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement ELBA No 765492.
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens

  • Pedraz Valdunciel, Carlos
  • Giannoukakos, Stavros Panagiotis
  • M Potie, Nicolas Thierry
  • Hackenberg, Michael|||0000-0003-2248-3114
  • Fernández Hilario, Alberto Luis|||0000-0002-6480-8434
We would like to thank Stephanie Davis for her language editing assistance. The investigators also wish to thank the patients for kindly agreeing to donate samples to this study. We thank all the physicians who collaborated by providing clinical information. Graphical Abstract, Figs 1A, 8A and Fig. S1 were created with Biorender.com. This project has received funding from a European Union's Horizon 2020 research and innovation program under the Marie SklodowskaCurie grant agreement ELBA No 765492., Although many studies highlight the implication of circular RNAs (circRNAs) in carcinogenesis and tumor progression, their potential as cancer biomarkers has not yet been fully explored in the clinic due to the limitations of current quantification methods. Here, we report the use of the nCounter platform as a valid technology for the analysis of circRNA expression patterns in non-small cell lung cancer (NSCLC) specimens. Under this context, our custom-made circRNA panel was able to detect circRNA expression both in NSCLC cells and formalin-fixed paraffinembedded (FFPE) tissues. CircFUT8 was overexpressed in NSCLC, contrasting with circEPB41L2, circBNC2, and circSOX13 downregulation even at the early stages of the disease. Machine learning (ML) approaches from different paradigms allowed discrimination of NSCLC from nontumor controls (NTCs) with an 8-circRNA signature. An additional 4-circRNA signature was able to classify early-stage NSCLC samples from NTC, reaching a maximum area under the ROC curve (AUC) of 0.981. Our results not only present two circRNA signatures with diagnosis potential but also introduce nCounter processing following ML as a feasible protocol for the study and development of circRNA signatures for NSCLC., European Commission 765492
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection

  • D’Ambrosi, Silvia
  • Giannoukakos, Stavros Panagiotis
  • M Potie, Nicolas Thierry
  • Hackenberg, Michael
  • Fernández Hilario, Alberto Luis|||0000-0002-6480-8434
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24054881/s1., Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity necessary to reach diagnostic utility. Combinatorial biomarker approaches may offer a more reliable diagnosis. Here, we investigated the synergistic contributions of circRNA and mRNA signatures derived from blood platelets as biomarkers for lung cancer detection. We developed a comprehensive bioinformatics pipeline permitting an analysis of platelet- circRNA and mRNA derived from non-cancer individuals and lung cancer patients. An optimal selected signature is then used to generate the predictive classification model using machine learning algorithm. Using an individual signature of 21 circRNA and 28 mRNA, the predictive models reached an area under the curve (AUC) of 0.88 and 0.81, respectively. Importantly, combinatorial analysis including both types of RNAs resulted in an 8-target signature (6 mRNA and 2 circRNA), enhancing the differentiation of lung cancer from controls (AUC of 0.92). Additionally, we identified five biomarkers potentially specific for early-stage detection of lung cancer. Our proof-of-concept study presents the first multi-analyte-based approach for the analysis of platelets-derived biomarkers, providing a potential combinatorial diagnostic signature for lung cancer detection., European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie 765492.
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies

  • Fortunato, Diogo
  • Giannoukakos, Stavros Panagiotis
  • Hackenberg, Michael|||0000-0003-2248-3114
Background: Intercellular communication is mediated by extracellular vesicles (EVs), as they enclose selectively packaged biomolecules that can be horizontally transferred from donor to recipient cells. Because all cells constantly generate and recycle EVs, they provide accurate timed snapshots of individual pathophysiological status. Since blood plasma circulates through the whole body, it is often the biofluid of choice for biomarker detection in EVs. Blood collection is easy and minimally invasive, yet reproducible procedures to obtain pure EV samples from circulating biofluids are still lacking. Here, we addressed central aspects of EV immunoaffinity isolation from simple and complex matrices, such as plasma. Methods: Cell-generated EV spike-in models were isolated and purified by size-exclusion chromatography, stained with cellular dyes and characterized by nano flow cytometry. Fluorescently-labelled spike-in EVs emerged as reliable, high-throughput and easily measurable readouts, which were employed to optimize our EV immunoprecipitation strategy and evaluate its performance. Plasma-derived EVs were captured and detected using this straightforward protocol, sequentially combining isolation and staining of specific surface markers, such as CD9 or CD41. Multiplexed digital transcript detection data was generated using the Nanostring nCounter platform and evaluated through a dedicated bioinformatics pipeline. Results: Beads with covalently-conjugated antibodies on their surface outperformed streptavidin-conjugated beads, coated with biotinylated antibodies, in EV immunoprecipitation. Fluorescent EV spike recovery evidenced that target EV subpopulations can be efficiently retrieved from plasma, and that their enrichment is dependent not only on complex matrix composition, but also on the EV surface phenotype. Finally, mRNA profiling experiments proved that distinct EV subpopulations can be captured by directly targeting different surface markers. Furthermore, EVs isolated with anti-CD61 beads enclosed mRNA expression patterns that might be associated to early-stage lung cancer, in contrast with EVs captured through CD9, CD63 or CD81. The differential clinical value carried within each distinct EV subset highlights the advantages of selective isolation. Conclusions: This EV isolation protocol facilitated the extraction of clinically useful information from plasma. Compatible with common downstream analytics, it is a readily implementable research tool, tailored to provide a truly translational solution in routine clinical workflows, fostering the inclusion of EVs in novel liquid biopsy settings., European Commission 765492 952183
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

sRNAbench and sRNAtoolbox 2022 update: accurate miRNA and sncRNA profiling for model and non-model organisms

  • Aparicio Puerta, Ernesto
  • Giannoukakos, Stavros Panagiotis
  • Medina Casaubón, José María|||0000-0003-1301-0139
  • García Moreno, Adrián
  • Carmona Sáez, Pedro|||0000-0002-6173-7255
  • Marchal Corrales, Juan Antonio|||0000-0002-4996-8261
  • Hackenberg, Michael|||0000-0003-2248-3114
European Union [765492 to M.H.]; Spanish Government [AGL2017-88702-C2-2-R to M.H.]; Chair 'Doctors Galera-Requena in cancer stem cell research' (to J.A.M.); Tromsoforskningsstiftelse (TFS) [20 SG BF 'MIRevolution' to B.F.]; Stichting Cancer Center Amsterdam [CCA2021-9-77 to C.G]; TKI-Health Holland ['AQrate' project to C.G. and M.P.]. This publication is part of a project that has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 765492., The NCBI Sequence Read Archive currently hosts microRNA sequencing data for over 800 different species, evidencing the existence of a broad taxonomic distribution in the field of small RNA research. Simultaneously, the number of samples per miRNA-seq study continues to increase resulting in a vast amount of data that requires accurate, fast and user-friendly analysis methods. Since the previous release of sRNAtoolbox in 2019, 55 000 sRNAbench jobs have been submitted which has motivated many improvements in its usability and the scope of the underlying annotation database. With this update, users can upload an unlimited number of samples or import them from Google Drive, Dropbox or URLs. Micro- and small RNA profiling can now be carried out using high-confidence Metazoan and plant specific databases, MirGeneDB and PmiREN respectively, together with genome assemblies and libraries from 441 Ensembl species. The new results page includes straightforward sample annotation to allow downstream differential expression analysis with sRNAde. Unassigned reads can also be explored by means of a new tool that performsmapping to microbial references, which can reveal contamination events or biologically meaningful findings as we describe in the example. sRNAtoolbox is available at: https://arn.ugr.es/srnatoolbox/., European Commission 765492, Spanish Government, European Commission AGL2017-88702-C2-2-R, Chair 'Doctors Galera-Requena in cancer stem cell research', Stichting Cancer Center Amsterdam CCA2021-9-77, Tromsoforskningsstiftelse (TFS) ['MIRevolution'] 20 SG BF, TKI-Health Holland ['AQrate' project]
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer

  • Pedraz Valdunciel, Carlos
  • Giannoukakos, Stavros Panagiotis
  • Fernández Hilario, Alberto Luis|||0000-0002-6480-8434
  • Hackenberg, Michael|||0000-0003-2248-3114
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients. Methods: EVs were isolated from early-stage LC patients (n = 36) and controls (n = 30). Different volumes of plasma, together with different number of preamplification cycles, were tested to reach the best nCounter outcome. Differential expression analysis of circRNAs was performed, along with the testing of different machine learning (ML) methods for the development of a prognostic signature for LC. Results: A combination of 500 L of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86. Conclusions: This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures., European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant 765492
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform

  • P. Bracht, Jillian W.
  • Gimenez‑Capitan, Ana
  • Huang, Chung‑Ying
  • M Potie, Nicolas Thierry
  • Pedraz Valdunciel, Carlos
  • Warren, Sarah
  • Rosell, Rafael
  • Molina‑Vila, Miguel A.
Extracellular vesicles (EVs) are double-layered phospholipid membrane vesicles that are released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform can be used for the analysis of EV-mRNA. We developed and optimized a methodology for EV enrichment, EV-RNA extraction and nCounter analysis. Then, we demonstrated the validity of our workflow by analyzing EV-RNA profiles from the plasma of 19 cancer patients and 10 controls and developing a gene signature to differentiate cancer versus control samples. TRI reagent outperformed automated RNA extraction and, although lower plasma input is feasible, 500 μL provided highest total counts and number of transcripts detected. A 10-cycle preamplification followed by DNase treatment yielded reproducible mRNA target detection. However, appropriate probe design to prevent genomic DNA binding is preferred. A gene signature, created using a bioinformatic algorithm, was able to distinguish between control and cancer EV-mRNA profiles with an area under the ROC curve of 0.99. Hence, the nCounter platform can be used to detect mRNA targets and develop gene signatures from plasma-derived EVs., European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement ELBA No. 765492
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

ALL-tRNAseq enables robust tRNA profiling in tissue samples

  • Scheepbouwe, Chantal
  • Aparicio Puerta, Ernesto
  • Giannoukakos, Stavros Panagiotis
  • Hackenberg, Michael|||0000-0003-2248-3114
This work was supported by the Dutch Cancer Society (KWF 2016-10476 to D.K.-L.), the Cancer Center Amsterdam Foundation (CCA2017-2-16 to D.K.-L.), and “Stichting MRD Hodgkin Lymphoma” (to D.M.P.). C.S was supported by a Cancer Center Amsterdam Foundation grant (CCA2021-5-26 to A.G.). A.G. was supported by the Nederlandse Organisatie voorWetenschappelijk Onderzoek (NWO) Talent Programme Vidi grant (VI.Vidi. 193.107). S.G., M.H., D.K.-L., and T.W. received funding from the European Union’s Horizon 2020 research and innovation programunder the Marie Skłodowska-Curie grant agreement number 765492. We thank Disa Tehler for stimulating discussions, and we are grateful to Hakan Kalay for assistance with the purification of AlkB enzymes.We thank Bram van den Broek for his contribution to the graphical images., Transfer RNAs (tRNAs) are small adaptor RNAs essential for mRNA translation. Alterations in the cellular tRNA population can directly affect mRNA decoding rates and translational efficiency during cancer development and progression. To evaluate changes in the composition of the tRNA pool, multiple sequencing approaches have been developed to overcome reverse transcription blocks caused by the stable structures of these molecules and their numerous base modifications. However, it remains unclear whether current sequencing protocols faithfully capture tRNAs existing in cells or tissues. This is specifically challenging for clinical tissue samples that often present variable RNA qualities. For this reason, we developed ALL-tRNAseq, which combines the highly processive MarathonRT and RNA demethylation for the robust assessment of tRNA expression, together with a randomized adapter ligation strategy prior to reverse transcription to assess tRNA fragmentation levels in both cell lines and tissues. Incorporation of tRNA fragments not only informed on sample integrity but also significantly improved tRNA profiling of tissue samples. Our data showed that our profiling strategy effectively improves classification of oncogenic signatures in glioblastoma and diffuse large B-cell lymphoma tissues, particularly for samples presenting higher levels of RNA fragmentation, further highlighting the utility of ALL-tRNAseq for translational research., Dutch Cancer Society (KWF 2016-10476 to D.K.-L.), Cancer Center Amsterdam Foundation (CCA2017-2-16 to D.K.-L.), “Stichting MRD Hodgkin Lymphoma”, Cancer Center Amsterdam Foundation grant (CCA2021-5-26 to A.G.), Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) Talent Programme Vidi grant (VI.Vidi. 193.107), European Union’s Horizon 2020 research and innovation programunder the Marie Skłodowska-Curie grant agreement number 765492
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Assessing the complementary information from an increased number of biologically relevant features in liquid biopsy-derived RNA-Seq data

  • Giannoukakos, Stavros Panagiotis
  • D’Ambrosi, Silvia
  • Koppers-Lalic, Danijela
  • Gómez Martín, Cristina
  • Fernández Hilario, Alberto Luis|||0000-0002-6480-8434
  • Hackenberg, Michael|||0000-0003-2248-3114
Liquid biopsy-derived RNA sequencing (lbRNA-seq) exhibits significant promise for clinicoriented cancer diagnostics due to its non-invasiveness and ease of repeatability. Despite substantial advancements, obstacles like technical artefacts and process standardisation impede seamless clinical integration. Alongside addressing technical aspects such as normalising fluctuating low-input material and establishing a standardised clinical workflow, the lack of result validation using independent datasets remains a critical factor contributing to the often low reproducibility of liquid biopsy-detected biomarkers. Considering the outlined drawbacks, our objective was to establish a workflow/methodology characterised by: 1. Harness the rich diversity of biological features accessible through lbRNA-seq data, encompassing a holistic range of molecular and functional attributes. These components are seamlessly integrated via a Machine Learning-based Ensemble Classification framework, enabling a unified and comprehensive analysis of the intricate information encoded within the data. 2. Implementing and rigorously benchmarking intra-sample normalisation methods to heighten their relevance within clinical settings. 3. Thoroughly assessing its efficacy across independent test sets to ascertain its robustness and potential utility. Using ten datasets from several studies comprising three different sources of biological material, we first show that while the best-performing normalisation methods depend strongly on the dataset and coupled Machine Learning method, the rather simple Counts Per Million method is generally very robust, showing comparable performance to cross-sample methods. Subsequently, we demonstrate that the innovative biofeature types introduced in this study, such as the Fraction of Canonical Transcript, harbour complementary information. Consequently, their inclusion consistently enhances prediction power compared to models relying solely on gene expressionbased biofeatures. Finally, we demonstrate that the workflow is robust on completely independent datasets, generally from different labs and/or different protocols. Taken together, the workflow presented here outperforms generally employed methods in prediction accuracy and may hold potential for clinical diagnostics application due to its specific design., European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement ELBA No 765492
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

  • Gonzalez-Cao, Maria
  • Cai, Xueting
  • Bracht, Jilian Wilhelmina Paulina
  • Han, Xuan
  • Yang, Yang
  • Pedraz-Valdunciel, Carlos
  • Morán, Teresa
  • García-Corbacho, Javier
  • Aguilar, Andrés
  • Bernabé, Reyes
  • De Marchi, Pedro
  • da Silva, Luciane Sussuchi
  • Ferro Leal, Leticia
  • Reis, Rui Manuel
  • Codony-Servat, Jordi
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Purpose: High-mobility group box 1 protein (HMGB1) is subject to exportin 1 (XPO1)-dependent nuclear export, and it is involved in functions implicated in resistance to immunotherapy. We investigated whether HMGB1 mRNA expression was associated with response to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). Patients and Methods: RNA was isolated from pretreatment biopsies of patients with advanced NSCLC treated with ICI. Gene expression analysis of several genes, including HMGB1, was conducted using the NanoString Counter analysis system (PanCancer Immune Profiling Panel). Western blotting analysis and cell viability assays in EGFR and KRAS mutant cell lines were carried out. Evaluation of the antitumoral effect of ICI in combination with XPO1 blocker (selinexor) and trametinib was determined in a murine Results: HMGB1 mRNA levels in NSCLC patients treated with ICI correlated with progression-free survival (PFS) (median PFS 9.0 versus 18.0 months, P=0.008, hazard ratio=0.30 in high versus low HMGB1). After TNF-alpha stimulation, HMGB1 accumulates in the cytoplasm of PC9 cells, but this accumulation can be prevented by using selinexor or antiretroviral drugs. Erlotinib or osimertinib with selinexor in EGFR-mutant cells and trametinib plus selinexor in KRAS mutant abolish tumor cell proliferation. Selinexor with a PD-1 inhibitor with or without trametinib abrogates the tumor growth in the murine Lewis lung cancer model. Conclusion: An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI., The investigators wish to thank the patients for kindly agreeing to donate samples to this study. We also thank all the physicians who collaborated by providing clinical information. This work was supported by a European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement ELBA [No 765492] , the National Science Foundation for Distinguished Young Scholars [82125037] , the Major National Science and Technology Program of China for Innovative Drug [2017ZX09101002-002-006] , and by the Key R&D Program of Jiangsu Province [BE2018755, HBZ2021-012] . This work was also partially supported by a Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE) and by the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer) . This work is in memory of the generous support provided by the late Julian Santamaria Valino to the IOR Foundation.r the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer) . This work is in memory of the generous support provided by the late Julian Santamaria Valino to the IOR Foundation.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Cancer

  • Bao-Caamano, Aida
  • Costa-Fraga, Nicolás
  • Cayrefourcq, Laure
  • Jácome, M. A.
  • Rodríguez-Casanova, Aitor
  • Muinelo Romay, Laura
  • López-López, Rafael
  • Alix-Panabières, Catherine
  • Díaz-Lagares, Ángel
[Abstract] Circulating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients., This research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from “Instituto de Salud Carlos III” (ISCIII) co-funded by “Fondo Social Europeo” (FSE). NC-F is funded by a predoctoral contract from “Xunta de Galicia” (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by “Axencia Galega de Innovación (GAIN), Vicepresidencia Segunda e Consellería de Economía, Empresa e Innovación”. LM-R is funded by a contract “Miguel Servet” from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. AD-L was funded by a contract “Juan Rodés” (JR17/00016) from “Instituto de Salud Carlos III” (ISCIII) and by Servizo Galego de Saúde (SERGAS). All authors have read the journal's policy on disclosure of potential conflicts of interest, and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research, Xunta de Galicia; IN606A-2020/004, Xunta de Galicia; IN853B 2018/03, Francia. Institut National du Cancer; INCa_Inserm_DGOS_12553
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection, The Phase 2 DURVAST Study

  • González-Cao, María
  • Morán, Teresa
  • Dalmau, Judith
  • García-Corbacho, Javier
  • Bracht, Jillian W. P.
  • Bernabé Caro, Reyes
  • Juan-Vidal, Óscar
  • Castro, Javier de
  • Blanco, Remei
  • Drozdowskyj, Ana
  • Argilaguet, Jordi
  • Meyerhans, Andreas
  • Blanco, Julià
  • Prado, Julia G.
  • Carrillo, Jorge
  • Clotet, Bonaventura
  • Massuti Sureda, Bartomeu
  • Provencio, Mariano
  • Molina-Vila, Miguel A.
  • Mayo de las Casa, Clara
  • Garzon, Monica
  • Cao, Peng
  • Huang, Chung-Ying
  • Martínez-Picado, Javier
  • Rosell, Rafael
[Importance] Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable clinical responses in several tumor types. However, concerns about the safety and feasibility of PD-1/PD-L1 blockade in HIV-1–infected individuals have led to the exclusion of these patients from clinical trials on cancer immunotherapies., [Objective] To evaluate the feasibility and safety of durvalumab treatment in patients with advanced cancer and virologically controlled HIV-1 infection., [Design, Setting, and Participants] The DURVAST study was a nonrandomized, open-label, phase 2 clinical trial in patients with any solid tumor type in which anti–PD-1 or anti–PD-L1 antibodies have approved indications or for which there are data of antitumoral activity with no other available curative therapy. All patients had basal undetectable plasma viremia while undergoing combination antiretroviral therapy., [Interventions] Treatment consisted of intravenous infusion of durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects., [Main Outcomes and Measures] Adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1., [Results] A total of 20 HIV-1–infected patients with advanced cancer were enrolled; 16 (80%) were male, the median (range) age was 54 (30-73) years, and 12 (60%) had progressed with previous cancer treatment lines. A median (range) of 4 (1-16) cycles of durvalumab were administered. Drug-related adverse events were observed in 50% of patients, and all were grade 1 and 2 (mainly diarrhea, asthenia, and arthromyalgia). Four of 16 response-evaluable patients (25%) had a partial response. Five patients (31%) had stable disease, including 4 with durable stable disease (disease control rate of 50%). CD4+ and CD8+ T-cell counts and plasma HIV-1 viremia remained stable throughout the study., [Conclusions and Relevance] Durvalumab treatment was feasible and safe in HIV-1–infected patients with cancer receiving combination antiretroviral therapy. HIV-1–infected patients on suppressive antiretroviral therapy with advanced cancer should have access to cancer immunotherapy treatments., [Trial Registration] ClinicalTrials.gov Identifier: NCT03094286., This study was sponsored by the Spanish Lung Cancer Group (SLCG) and supported by the AstraZeneca Group. A Marie Skłodowska-Curie Innovative Training Networks European Grant (ELBA No. 765492), the Spanish Association Against Cancer (AECC) (grant No.PROYE18012ROSE), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) supported in part the associated translational study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

  • González Cao, María
  • Montagut Viladot, Clara
  • Berrocal Jaime, Alfonso
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the "on-off" schedule. Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516). The trial did not meet its primary endpoint of progression free survival (PFS) improvement. Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule. Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression. NGS analysis demonstrated de novo mutations in resistant cases.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Activation of viral defense signaling in cancer

  • Gonzalez-Cao, Maria
  • Karachaliou, Niki
  • Santarpia, Mariacarmela
  • Viteri, Santiago
  • Meyerhans, Andreas
  • Rosell, Rafael
A coordinated action of innate and adaptive immune responses is required to efficiently combat a microbial infection. It has now become clear that cancer therapies also largely benefit when both arms of the immune response are engaged. In this review, we will briefly describe the current knowledge of innate immunity and how this can be utilized to prime tumors for a better response to immune checkpoint inhibitors. Comments on compounds in development and ongoing clinical trials will be provided., AM is supported by a grant from the Spanish Ministry of Economy, Industry and Compet-itiveness and FEDER grant no. SAF2016-75505-R (AEI/MINEICO/FEDER, UE), and the ‘María de Maeztu’ Programme for Units of Excellence in R&D (MDM-2014-0370). Work in Dr Rosell’s laboratory is partially supported by a grant from La Caixa Foundation, and by a European Grant (ELBA no 765492).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multiplex analysis of circRNAs from plasma extracellular vesicle-enriched samples for the detection of early-stage non-small cell lung cancer

  • Pedraz-Valdunciel, Carlos
  • Giannoukakos, Stavros
  • Giménez-Capitán, Ana
  • Fortunato, Diogo
  • Filipska, Martyna
  • Bertran-Alamillo, Jordi
  • Bracht, Jillian W.P.
  • Drozdowskyj, Ana
  • Valarezo, Joselyn
  • Zarovni, Natasa
  • Fernández-Hilario, Alberto
  • Hackenberg, Michael
  • Aguilar-Hernández, Andrés
  • Molina-Vila, Miguel Ángel
  • Rosell, Rafael
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients. Methods: EVs were isolated from early-stage LC patients (n = 36) and controls (n = 30). Different volumes of plasma, together with different number of pre-amplification cycles, were tested to reach the best nCounter outcome. Differential expression analysis of circRNAs was performed, along with the testing of different machine learning (ML) methods for the development of a prognostic signature for LC. Results: A combination of 500 μL of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86. Conclusions: This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures., This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement ELBA No 765492.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial, The need for a new pre-clinical treatment rationale

  • Bracht, Jillian|||0000-0001-9552-3960
  • Karachaliou, Niki
  • Bivona, Trever
  • Lanman, Richard B.
  • Faull, Iris
  • Nagy, Rebecca J.
  • Drozdowskyj, Ana
  • Berenguer, Jordi
  • Fernandez-Bruno, Manuel
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
  • Rosell, Rafael|||0000-0003-0817-3400
BRAF V600 mutations have been found in 1-2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50-80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed advanced lung adenocarcinoma patients (Spanish Lung Liquid versus Invasive Biopsy Program, SLLIP, NCT03248089) was examined for BRAF and other alterations with a targeted cfDNA next-generation sequencing (NGS) assay (Guardant360®, Guardant Health Inc., CA, USA), and results were correlated with patient outcome. Cell viability with single or combined RAF, MEK, and SHP2 inhibitors was assessed in cell lines with BRAF class I, II, and III mutations. Out of 185 patients, 22 had BRAF alterations (12%) of which seven patients harbored amplifications (32%) and 17 had BRAF mutations (77%). Of the BRAF mutations, four out of 22 (18%) were V600E and 18/22 (82%) were non-V600. In vitro results confirmed sensitivity of class III and resistance of class I and II BRAF mutations, and BRAF wild type cells to SHP2 inhibition. Concomitant MEK or RAF and SHP2 inhibition showed synergistic effects, especially in the class III BRAF-mutant cell line. Our study indicates that the class of the BRAF mutation may have clinical implications and therefore should be defined in the clinical practice and used to guide therapeutic decisions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment

  • Filipska, Martyna|||0000-0001-9947-4561
  • Rosell, Rafael|||0000-0003-0817-3400
Over the past decade, substantial developments have been made in the detection of circulating tumor DNA (ctDNA)-cell-free DNA (cfDNA) fragments released into the circulation from tumor cells and displaying the genetic alterations of those cells. As such, ctDNA detected in liquid biopsies serves as a powerful tool for cancer patient stratification, therapy guidance, detection of resistance, and relapse monitoring. In this Review, we describe lung cancer diagnosis and monitoring strategies using ctDNA detection technologies and compile recent evidence regarding lung cancer-related mutation detection in liquid biopsy. We focus not only on epidermal growth factor receptor (EGFR) alterations, but also on significant co-mutations that shed more light on novel ctDNA-based liquid biopsy applications. Finally, we discuss future perspectives of early-cancer detection and clonal hematopoiesis filtering strategies, with possible inclusion of microbiome-driven liquid biopsy. Liquid biopsy can greatly contribute to better detection and management of lung cancer. ctDNA detection in liquid biopsies is a powerful tool for early detection, cancer patient stratification, therapy guidance, detection of resistance, and relapse monitoring. We describe lung cancer diagnosis and monitoring strategies using ctDNA detection technologies and compile recent evidence on the identification of lung cancer-related mutations through liquid biopsy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform

  • Bracht, Jillian|||0000-0001-9552-3960
  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Huang, Chung-Ying
  • Potie, Nicolas
  • Pedraz-Valdunciel, Carlos|||0000-0002-3163-2444
  • Warren, Sarah
  • Rosell, Rafael|||0000-0003-0817-3400
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
Extracellular vesicles (EVs) are double-layered phospholipid membrane vesicles that are released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform can be used for the analysis of EV-mRNA. We developed and optimized a methodology for EV enrichment, EV-RNA extraction and nCounter analysis. Then, we demonstrated the validity of our workflow by analyzing EV-RNA profiles from the plasma of 19 cancer patients and 10 controls and developing a gene signature to differentiate cancer versus control samples. TRI reagent outperformed automated RNA extraction and, although lower plasma input is feasible, 500 μL provided highest total counts and number of transcripts detected. A 10-cycle pre-amplification followed by DNase treatment yielded reproducible mRNA target detection. However, appropriate probe design to prevent genomic DNA binding is preferred. A gene signature, created using a bioinformatic algorithm, was able to distinguish between control and cancer EV-mRNA profiles with an area under the ROC curve of 0.99. Hence, the nCounter platform can be used to detect mRNA targets and develop gene signatures from plasma-derived EVs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform

  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Bracht, Jillian|||0000-0001-9552-3960
  • García Mosquera, Juan José|||0000-0001-5165-4168
  • Jordana-Ariza, Núria
  • García Peláez, Beatriz
  • Garzón Ibáñez, Mónica
  • Mayo-de-las-Casas, Clara
  • Viteri, Santiago|||0000-0002-7572-1123
  • Martínez-Bueno, Alejandro
  • Aguilar-Hernández, Andrés
  • Sullivan, Ivana|||0000-0002-0434-3436
  • Johnson, Eric
  • Huang, Chung-Ying
  • Gerlach, Jay L.|||0000-0002-4980-3774
  • Warren, Sarah
  • Beechem, Joseph M.|||0000-0001-8372-5899
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Rosell, Rafael|||0000-0003-0817-3400
  • Reguart, Noemi|||0000-0001-8190-499X
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
BACKGROUND: With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. The nCounter platform could be an alternative, but it has never been explored for detection of clinically relevant alterations in fluids. METHODS: Circulating-free DNA (cfDNA) was purified from blood, cerebrospinal fluid, and ascites of patients with cancer and analyzed with the nCounter 3 D Single Nucleotide Variant (SNV) Solid Tumor Panel, which allows for detection of 97 driver mutations in 24 genes. RESULTS: Validation experiments revealed that the nCounter SNV panel could detect mutations at allelic fractions of 0.02-2% in samples with 5 pg mutant DNA/mL. In a retrospective analysis of 70 cfDNAs from patients with cancer, the panel successfully detected EGFR, KRAS, BRAF, PIK3CA, and NRAS mutations when compared with previous genotyping in the same liquid biopsies and paired tumor tissues [Cohen kappa of 0.96 (CI = 0.92-1.00) and 0.90 (CI = 0.74-1.00), respectively]. In a prospective study including 91 liquid biopsies from patients with different malignancies, 90 yielded valid results with the SNV panel and mutations in EGFR, KRAS, BRAF, PIK3CA, TP53, NFE2L2, CTNNB1, ALK, FBXW7, and PTEN were found. Finally, serial liquid biopsies from a patient with NSCLC revealed that the semiquantitative results of the mutation analysis by the SNV panel correlated with the evolution of the disease. CONCLUSIONS: The nCounter platform requires less DNA than NGS and can be employed for routine mutation testing in liquid biopsies of patients with cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer

  • Pedraz-Valdunciel, Carlos|||0000-0002-3163-2444
  • Giannoukakos, Stavros|||0000-0001-8190-4199
  • Giménez-Capitán, A.
  • Fortunato, D.
  • Filipska, Martyna|||0000-0001-9947-4561
  • Bertran-Alamillo, Jordi|||0000-0002-4447-4748
  • Bracht, Jillian|||0000-0001-9552-3960
  • Drozdowskyj, Ana
  • Valarezo, J.
  • Zarovni, N.
  • Fernandez Hilario, Alberto|||0000-0002-6480-8434
  • Hackenberg, Michael|||0000-0003-2248-3114
  • Aguilar-Hernández, Andrés
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
  • Rosell, Rafael|||0000-0003-0817-3400
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. However, standardized and robust protocols need to be developed to boost their potential in the clinical setting. Although nCounter has been used for the analysis of other liquid biopsy substrates and biomarkers, it has never been employed for EV-circRNA analysis of LC patients. Methods: EVs were isolated from early-stage LC patients (n = 36) and controls (n = 30). Different volumes of plasma, together with different number of pre-amplification cycles, were tested to reach the best nCounter outcome. Differential expression analysis of circRNAs was performed, along with the testing of different machine learning (ML) methods for the development of a prognostic signature for LC. Results: A combination of 500 μL of plasma input with 10 cycles of pre-amplification was selected for the rest of the study. Eight circRNAs were found upregulated in LC. Further ML analysis selected a 10-circRNA signature able to discriminate LC from controls with AUC ROC of 0.86. Conclusions: This study validates the use of the nCounter platform for multiplexed EV-circRNA expression studies in LC patient samples, allowing the development of prognostic signatures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens

  • Pedraz-Valdunciel, Carlos|||0000-0002-3163-2444
  • Giannoukakos, Stavros|||0000-0001-8190-4199
  • Potie, Nicolas
  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Huang, Chung-Ying
  • Hackenberg, Michael|||0000-0003-2248-3114
  • Fernandez-Hilario, Alberto
  • Bracht, Jillian|||0000-0001-9552-3960
  • Filipska, Martyna|||0000-0001-9947-4561
  • Aldeguer, Erika
  • Rodríguez, Sonia
  • Bivona, Trever
  • Warren, Sarah
  • Aguado, Cristina
  • Ito, Masaoki
  • Aguilar-Hernández, Andrés
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
  • Rosell, Rafael|||0000-0003-0817-3400
Although many studies highlight the implication of circular RNAs (circRNAs) in carcinogenesis and tumor progression, their potential as cancer biomarkers has not yet been fully explored in the clinic due to the limitations of current quantification methods. Here, we report the use of the nCounter platform as a valid technology for the analysis of circRNA expression patterns in non-small cell lung cancer (NSCLC) specimens. Under this context, our custom-made circRNA panel was able to detect circRNA expression both in NSCLC cells and formalin-fixed paraffin-embedded (FFPE) tissues. CircFUT8 was overexpressed in NSCLC, contrasting with circEPB41L2, circBNC2, and circSOX13 downregulation even at the early stages of the disease. Machine learning (ML) approaches from different paradigms allowed discrimination of NSCLC from nontumor controls (NTCs) with an 8-circRNA signature. An additional 4-circRNA signature was able to classify early-stage NSCLC samples from NTC, reaching a maximum area under the ROC curve (AUC) of 0.981. Our results not only present two circRNA signatures with diagnosis potential but also introduce nCounter processing following ML as a feasible protocol for the study and development of circRNA signatures for NSCLC. Aberrant circular RNA (circRNA) expression is present in lung cancer. Using nCounter with machine learning, we discovered two signatures able to discriminate FFPE lung cancer samples from controls even at early stage. Our results not only highlight the potential of circRNAs as lung cancer biomarkers but also introduce nCounter as a suitable platform for circRNA expression studies in these samples.